DCM
PBYI icon

DGS Capital Management’s Puma Biotechnology PBYI Stock Holding History

DGS Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.6K Buy
+10,418
New +$67.2K 0.01% 605

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

DGS Capital Management's PBYI Position: Q1 2026 in Review

DGS Capital Management opened a new position in Puma Biotechnology (PBYI) in Q1 2026: 10,418 shares worth $66.6K. The stake represents 0.01% of the portfolio and ranks #605 among its holdings.

157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • DGS Capital Management held 10,418 shares of Puma Biotechnology worth $66.6K as of Q1 2026.
  • Puma Biotechnology was a new DGS Capital Management position in Q1 2026.
  • Puma Biotechnology made up 0.01% of DGS Capital Management's portfolio in Q1 2026, its #605 holding.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.